(-)-(3R)-1-(4-fluoro-2-methoxybenzyl)-N-(9-chloro-3 ,4-dihydro-2H-1,5-benzodioxepin-7-ylmethyl)-N-isobutylpyrrolidine-3-carboxamide | 1233926-88-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (-)-(3R)-1-(4-fluoro-2-methoxybenzyl)-N-(9-chloro-3 ,4-dihydro-2H-1,5-benzodioxepin-7-ylmethyl)-N-isobutylpyrrolidine-3-carboxamide
• 英文别名: US8722896, (-)-(3R)-1-(4-Fluoro-2-methoxybenzyl)-N-(9-chloro-3,4-dihydro-2H-1,5-benzodioxepin-7-ylmethyl)-N-isobutylpyrrolidine-3-carboxamide；(3R)-N-[(6-chloro-3,4-dihydro-2H-1,5-benzodioxepin-8-yl)methyl]-1-[(4-fluoro-2-methoxyphenyl)methyl]-N-(2-methylpropyl)pyrrolidine-3-carboxamide
• CAS: 1233926-88-9
• 化学式: C₂₇H₃₄ClFN₂O₄
• 分子量: 505.029
• InChiKey: CUWXIGJERCHVDB-OAQYLSRUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  51.2
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Prokineticin Receptor Antagonists And Uses Thereof
  申请人：Zhou Qun-Yong

  公开号：US20120035149A1

  公开（公告）日：2012-02-09

  Contemplated compounds, compositions, and methods of prokineticin antagonists are presented where a prokineticin antagonist is used in the treatment and prevention of various conditions and disorders, and especially type II diabetes.

  本文提出了一种思考过的化合物、组合物和拮抗前动素方法，其中使用拮抗前动素用于治疗和预防各种疾病和疾病，尤其是2型糖尿病。
• Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US10780095B2

  公开（公告）日：2020-09-22

  In alternative embodiments, provided are methods for: modifying circadian rhythmicity or timing in a mammal, treating psychiatric conditions or symptoms due to alterations in a human circadian regulatory system, treating sleep problems in a mammal, or inducing sleep or activity suppression, or causing an arousal or wakening reaction, comprising administration to a mammal or human a compound or composition capable of modifying a prokineticin 2 (PK2) expression or activity, and/or a PKR2 (PK2 receptor), a vasopressin receptor (VR), and/or a melatonin receptor (MR) expression or activity.

  在另一个实施方案中，提供了用于以下方面的方法改变哺乳动物的昼夜节律性或时间，治疗由于人类昼夜节律调节系统的改变而引起的精神状况或症状，治疗哺乳动物的睡眠问题，或诱导睡眠或活动抑制，或引起唤醒或觉醒反应、包括向哺乳动物或人类施用一种化合物或组合物，该化合物或组合物能够改变促激肽2（PK2）的表达或活性，和/或PKR2（PK2受体）、血管加压素受体（VR）和/或褪黑激素受体（MR）的表达或活性。
• COMPOSITIONS AND METHODS FOR TREATING DISORDERS OF CIRCADIAN AND DIURNAL RHYTHMS USING PROKINETICIN 2 AGONISTS AND ANTAGONISTS
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20190117668A1

  公开（公告）日：2019-04-25

  In alternative embodiments, provided are methods for: modifying circadian rhythmicity or timing in a mammal, treating psychiatric conditions or symptoms due to alterations in a human circadian regulatory system, treating sleep problems in a mammal, or inducing sleep or activity suppression, or causing an arousal or wakening reaction, comprising administration to a mammal or human a compound or composition capable of modifying a prokineticin 2 (PK2) expression or activity, and/or a PKR2 (PK2 receptor), a vasopressin receptor (VR), and/or a melatonin receptor (MR) expression or activity.
• US8722896B2
  申请人：——

  公开号：US8722896B2

  公开（公告）日：2014-05-13